Business Context and Reporting Period
This Form 8-K is a Current Report filed by Oragenics, Inc. (also referred to as ONI BioPharma Inc.) on January 15, 2009. The report discloses a Regulation FD event where the Company's CEO and Chief Scientific Officer presented a PowerPoint presentation and Fact Sheet to interested persons in Paris, France. The presentation highlighted the Company's product divisions, the recent launch of EvoraPlus, and the listing of its common stock on the Alternext Paris exchange.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a presentation event rather than a financial statement. The document references the Company's Form 10-K for the year ended December 31, 2007, and Form 10-Q for the quarter ended September 30, 2008, for detailed financial information.
Material Changes
The filing does not report material changes to financial results compared to prior periods. The primary material event disclosed is the strategic communication regarding the recent listing on the Alternext Paris exchange and the marketing focus on the EvoraPlus product line.
Guidance, Outlook, and Risks
- Outlook: Management emphasized EvoraPlus as the expected revenue base for other divisions.
- Regulatory Status: The information in the attached presentation and fact sheet is furnished under Item 7.01 and is not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
- Forward-Looking Statements: The Company undertakes no duty to update or revise the information contained in this report.
Investor Verification Checklist
- Verify the details of the EvoraPlus launch and its projected role as a revenue base by reviewing the attached Exhibit 99.1 (Presentation) and Exhibit 99.2 (Fact Sheet).
- Confirm the status and trading details of the common stock listing on the Alternext Paris exchange.
- Review the Form 10-K for the year ended December 31, 2007, and the Form 10-Q for the quarter ended September 30, 2008, for actual financial performance data not included in this 8-K.
- Note that the information provided is not subject to the liabilities of Section 18 of the Exchange Act.